biolitec AG
biolitec AG: revenue increased by 19% to 26.1 million Euro in the first three quarters of the fiscal year 2010/11 – Asia and Near East show high sales potentials with 73% growth
biolitec AG / Key word(s): Interim Report 31.05.2011 10:42 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- biolitec AG: revenue increased by 19% to 26.1 million Euro in the first three quarters of the fiscal year 2010/11 - Asia and Near East show high sales potentials with 73% growth Jena/Germany, May 31, 2011 - biolitec AG, listed in the Prime Standard of the Frankfurt stock exchange (ISIN DE0005213409), technology leader in minimally invasive laser therapy, realized a revenue of 26.1 million Euro (previous year: 21.8 million Euro) in the first three quarters of the fiscal year 2010/11. With this, biolitec has exceeded the previous year's result in the reference period by 4.3 million Euro, which is an increase of 19.1%. The revenue in Europe amounted to 11.7 million Euro (previous year: 10.4 million Euro). With 9.4 million Euro, sales in the USA again increased by 10% at the end of the third quarter. In Asia and 'rest of the world', biolitec generated a sales growth of 73% to more than 4.9 million Euro (pervious year: 2.8 million Euro.) The foreign subsidiaries, especially in the Arab world and Asia, currently contribute already near to 19% to the total turnover. Medium-term objecitve is to increase the share of these markets on biolitec's revenues to 30% und thereby tap new future global market potentials The gross profit amounted to 18.5 million Euro (previous year: 15 million Euro). The EBIT amounts to 1.49 million Euro at the end of the third quarter of the fiscal year 2010/11 und thus is at the level of the reference period of 09/10. The 9-month-operating-result 2010/11 with 1.67 million Euro is slightly higher than the previous year's result (previous year: 1.62 million Euro). The rationalization and diversification strategies and the strengthening of the global presence particularly in Asia and the Near East significantly contributed to this positive result. The business segment pharmaceuticals posted a turnover of 0.99 million Euro in the first three quarters. On a medium term, Biolitec AG expects to extend the sales and profit potential in this segment through increased sales activities in cooperation with the pharma-marketing partners as well as through the realized cost reimbursement in the Netherlands and Italy. Stocks levels could be reduced significantly in the reporting period, as well as lease obligations. In the first nine months of the fiscal year 2010/11, biolitec's research and development expenses increased to 3.1 million Euro (previous year 2.1 million Euro). As technology leader in minimally invasive laser therapies, e.g. the reimbursable ELVeS(R) laser system for vein treatment or the BPH treatment LIFE(TM), biolitec constantly develops new light fiber for special therapeutical treatments and leading medical laser technology procedures. Laser treatment is not only harmless, but also painless and quick. Also side effects which appear when taking drugs for many years do not occur. The new HeLP(TM)-Therapy for second and forth degree haemorrhoids in accordance with LHP(TM) method (Laser hemorrhoidoplasty) is a new innovative laser technology for ambulant treatment of haemorrhoids with a high growth potential, corresponding to the patients' desire for a secure and painless treatment. Biolitec's mainstay of sales are laser and disposables (catheter, laser fiber) for the BPH treatment LIFE(TM) as well as for the ELVeS(TM) vein treatment method. Further growth is expected in the business segment applications in aesthetics, especially for laser body forming and for medical haemorrhoid treatment. For the fourth quarter biolitec expects the positive sales trend to continue. 31.05.2011 DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: biolitec AG Otto-Schott-Str.15 07745 Jena Deutschland Phone: +49 (0) 3641 519 53 0 Fax: +49 (0) 3641 519 53 33 E-mail: info@biolitec.de Internet: www.biolitec.de ISIN: DE0005213409 WKN: 521340 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, München, Stuttgart End of Announcement DGAP News-Service ---------------------------------------------------------------------------
Aktuelle News
Aktuelle Berichte
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden